Description of Operations and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Description of Operations and Summary of Significant Accounting Policies
Decrease to accumulated deficit	$ 37,200
Reduction to Additional Paid in Capital	65,400
Equity and long-term investments	544,437		$ 483,845
Sale of equity investments managed by ISP FUND LP	24,281	$ 2,387
Purchase and sales of other investments managed by ISP Fund LP, net	132,266	(110,200)
Purchases of equity investments managed by ISP Fund LP	(2,015)	(112,587)
Increase in Deferred Tax Assets	7,400
Prior Period Immaterial Correction
Description of Operations and Summary of Significant Accounting Policies
Sale of equity investments managed by ISP FUND LP		2,400
Purchase and sales of other investments managed by ISP Fund LP, net		110,200
Purchases of equity investments managed by ISP Fund LP		$ (112,600)
Convertible senior notes
Description of Operations and Summary of Significant Accounting Policies
Increase in convertible notes	$ 35,600
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK
Description of Operations and Summary of Significant Accounting Policies
Percentage of economic interest in any future payments made under the agreements	15.00%
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO
Description of Operations and Summary of Significant Accounting Policies
Royalty rate for first level of annual global net sales (as a percent)	15.00%
Annual global sales level used to determine royalty rate	$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)	5.00%
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum
Description of Operations and Summary of Significant Accounting Policies
Royalty rate for combination products (as a percent)	6.50%
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum
Description of Operations and Summary of Significant Accounting Policies
Royalty rate for combination products (as a percent)	10.00%